Weekly Psychedelic Policy Briefing: October 12, 2026

Weekly Psychedelic Policy Briefing: October 12th, 2026

By Jack Gorsline

In this week's psychedelic policy briefing, investigative journalist and Psychedelic State(s) of America founder Jack Gorsline breaks down the details of three policy developments. First, the Food and Drug Administration is soliciting public feedback on how to safely structure and monitor the initial federally funded clinical trials involving ibogaine. Second, Compass Pathways executives have discussed launch pricing for COMP360, the company's psilocybin treatment, as Compass works to complete its new drug application this quarter. Third, state-level cannabis regulators are expressing frustration over unanswered questions from the Drug Enforcement Administration regarding marijuana's rescheduling. Any psychedelic drug the FDA approves will also depend on DEA action, and on DEA coordination with states, before it reaches patients.

Federal Regulatory: FDA Seeks Public Input on Ibogaine Trial Design

On October 5, the Food and Drug Administration issued a formal request for information under docket FDA-2026-N-10429, seeking input from researchers, clinicians, prospective sponsors, patients, and the broader public regarding the safety, dosing, and oversight of early-phase ibogaine clinical trials. These federally backed trials, funded by the National Institute on Drug Abuse and the Advanced Research Projects Agency for Health (ARPA-H), are expected to enroll adults with post-traumatic stress disorder (PTSD) and opioid use disorder (OUD), aligning with Executive Order 14401 signed in April. The only related study the notice says FDA has allowed to proceed is an early-phase trial of noribogaine, an ibogaine derivative, for alcohol use disorder. Because ibogaine presents severe cardiac risks, particularly QTc interval prolongation, which is linked to fatal ventricular arrhythmias and death, the agency has outlined strict preliminary safety measures. Under this proposed framework, small cohorts would receive a single dose each, escalating from one group to the next, with a starting dose not exceeding 10 mg/kg. The notice also asks commenters whether 10 mg/kg is the right ceiling. Administration would occur in an inpatient setting equipped for continuous cardiac rhythm monitoring, advanced life support, and emergency pacing, with continuous monitoring that could last up to 36 hours and an inpatient stay of at least that long. At least two staff members, including one licensed mental health professional, would closely supervise each patient during the drug's acute effects. Low potassium, calcium, or magnesium levels would need to be corrected prior to dosing, and trial sponsors could explore whether intravenous magnesium pretreatment mitigates these cardiac risks.

The agency clarified that these guidelines do not establish legally binding requirements and will not predetermine the outcome of any investigational new drug applications. For OUD patients, FDA's draft design would have participants stop opioid agonist treatments like buprenorphine and methadone before receiving ibogaine, prompting the FDA to ask for advice on managing the associated risks, such as a dangerous loss of opioid tolerance. The agency noted it is not seeking comments on ibogaine's legalization, religious use, or its status as a Schedule I drug. Separately, ARPA-H is requesting proposals for early-phase ibogaine trials through its ASCENT-IBO program, an initiative not explicitly named in the FDA notice. The deadline for submitting comments to the FDA docket is November 20.

Industry: Compass Pathways Talks Pricing as Psilocybin NDA Nears Completion

Compass Pathways has reported positive results from two Phase 3 studies, COMP005 and COMP006, for its synthetic psilocybin formulation, COMP360, aimed at treatment-resistant depression. The COMP005 trial evaluated a single 25 mg dose against a placebo, while COMP006 assessed two fixed doses administered three weeks apart. In July, the company shared six-month data from the COMP006 trial demonstrating lasting therapeutic benefits, and indicated that its rolling new drug application was in progress with final submission anticipated in the fourth quarter of this year. Having been granted a rolling submission in April along with a Commissioner's National Priority Voucher, Compass anticipates the federal review period could be condensed to just one or two months.

Psychedelic Alpha reported that company executives have discussed launch pricing and insurance payer reimbursement strategies, drawing comparisons to Spravato, an esketamine nasal spray produced by Johnson & Johnson. Spravato's label requires a strict Risk Evaluation and Mitigation Strategy (REMS) program involving twice-weekly treatments initially, followed by ongoing sessions that require at least two hours of in-clinic monitoring. Compass is positioning COMP360 against that schedule: in COMP006, two doses produced benefits that lasted at least six months, and the company argues patients may need only a few treatments a year. If approved, COMP360 would not become immediately available to patients. The company projects a commercial rollout in the first half of 2027, which remains contingent upon both FDA approval and the subsequent rescheduling of the product by the DEA.

Psychedelic-Adjacent: State Regulators Say DEA Hasn't Answered Their Rescheduling Questions

State cannabis regulators are reporting a lack of communication from the DEA regarding the implementation of the April 2026 order from Attorney General Todd Blanche that moved state-licensed medical marijuana and FDA-approved marijuana products to Schedule III, as covered by Marijuana Moment on October 7. During a public meeting the prior week, the executive director of the Georgia Access to Medical Cannabis Commission said the DEA told the commission it was not able to comment on state labeling proposals designed to match federal warning requirements. The chair of the Vermont Cannabis Control Board noted that a national association of state regulators has faced "radio silence" after submitting a list of questions to the agency. The regulators' primary concerns involve DEA registration and product labeling protocols. Vermont officials also highlighted a need for federal tax guidance, which would need to be issued by tax authorities rather than the DEA. Maryland regulators pointed out that the April order already exempts state medical marijuana businesses from the Section 280E tax penalty for the 2026 fiscal year.

In the background, two federal legal proceedings concerning marijuana rescheduling remain unresolved. On September 29, a DEA administrative law judge paused a separate hearing on broad marijuana rescheduling, giving the government until October 13 to respond to opposition motions. Meanwhile, the Justice Department and groups challenging the April order, such as Smart Approaches to Marijuana, submitted a joint proposed briefing schedule to the U.S. Court of Appeals for the D.C. Circuit on October 9. If the court adopts this timeline, opening briefs would be due on November 24, with final briefs expected by February 19, 2027. An FDA-approved psychedelic would not go through this litigation. It follows a faster statutory track. Under 21 U.S.C. § 811(j), the attorney general must issue an interim final scheduling rule within 90 days after a drug is approved and the Department of Health and Human Services recommends placing it in Schedule II through V. Compass has said its launch depends on this step, and on states. The company says states home to about 90% of U.S. patients intend to reschedule within 30 days of DEA action, which assumes the kind of DEA coordination that state cannabis regulators say they are not getting. Currently, neither MDMA nor psilocybin is approved, and both remain investigational.

Disclosures and Editorial Transparency Psychedelic State(s) of America (PSA), established by author Jack Gorsline, engages in collaborative initiatives with the Psychedelic Bar Association and maintains active educational and editorial partnerships with Psychedelics Today.